Caspofungin Acetate for Injection
Pack Sizes Available
Product Description
Technical Specifications
- Drug Class: Echinocandin antifungal
- Available Strengths: 50mg and 70mg per vial
- Dosage Form: Lyophilized powder for reconstitution and IV infusion
- Administration Route: Intravenous infusion only, over approximately 1 hour
- Standard Regimen: 70mg loading dose on day 1, followed by 50mg once daily
- Storage Condition: Store refrigerated (2 to 8 degrees C), protect from light
- Shelf Life: 24 to 36 months from date of manufacture
- Primary Indications: Invasive candidiasis, candidemia, esophageal candidiasis, invasive aspergillosis
Caspofungin Acetate is an echinocandin-class antifungal used to treat invasive candidiasis, candidemia, esophageal candidiasis, and invasive aspergillosis, typically in patients who have not responded to or cannot tolerate other antifungal therapies such as amphotericin B or azoles. It is administered as a slow intravenous infusion in hospital or critical care settings.
Adults typically receive a single 70mg loading dose on the first day of treatment, followed by 50mg once daily for the remainder of the treatment course. Dose adjustments may be required in patients with moderate hepatic impairment or those on certain interacting medications, and the exact regimen should always follow the prescribing physician's instructions.
The lyophilized powder is reconstituted with the recommended diluent, then further diluted before administration as a slow intravenous infusion over approximately one hour. It should not be administered as a bolus injection, and mixing with other medications in the same infusion line is generally avoided unless compatibility has been confirmed.
Unopened vials should be stored under refrigeration as specified by the manufacturer, protected from light. Once reconstituted, the solution has a limited window of chemical stability and should be used within the timeframe specified on the product insert, with any unused portion discarded rather than stored for later use.
Because standard dosing calls for a higher loading dose followed by a lower daily maintenance dose, pharmacies that stock only one strength end up either overdosing or wasting product on day one. Carrying both strengths in inventory allows the full treatment course to be dispensed correctly without recalculating partial vials.
Caspofungin has fewer drug interactions than azole antifungals because it does not rely heavily on the same liver enzyme pathways, which makes it a common choice for critically ill patients already on complex medication regimens. Even so, interactions with drugs like cyclosporine, tacrolimus, and certain anticonvulsants should be reviewed by the treating physician before use.
Colistimethate Sodium for Injection 1 MIU
There is a certain irony in colistin's comeback story. A drug developed in the 1950s, largely shelved for decades because of its reputation for kidney toxicity, is now one of the last reliable options standing against multidrug-resistant gram-negative bacteria that shrug off almost everything newer. Hospitals reach for Colistimethate Sodium when Klebsiella, Pseudomonas, or Acinetobacter infections have outmanoeuvred the usual carbapenem lineup, which places this product firmly in the last-line antibiotic category rather than a routine one. Colistimethate is the inactive prodrug form of colistin, converted to its active state in the body after administration, and the 1 MIU vial represents the smaller of the commonly stocked strengths, useful for weight-based dosing in patients where a full higher-strength vial would overshoot the calculated requirement. It's supplied as a lyophilized powder reconstituted before intravenous infusion, and correct reconstitution matters more here than with most antibiotics given the narrow therapeutic window between an effective dose and one that stresses the kidneys. For an exporter, colistin is not a casual product line. Regulatory bodies worldwide have tightened oversight on it precisely because of its toxicity profile and its status as a treatment of last resort, which means importers expect airtight documentation before they will even quote a price to their own institutional buyers. Every batch we supply travels with full analytical certification, stability data, and manufacturing traceability, because a tender for a critical care antibiotic will get rejected outright if the paperwork has gaps. Cold chain handling from the point of lyophilization to the point of delivery is non-negotiable, and we treat it that way rather than as a checkbox. Distributors serving ICUs and infectious disease units don't have room for a shipment that arrives compromised, not when the patients receiving it are often already critically ill with limited remaining treatment options. One pattern we've noticed working with importers over 15 years is that colistin orders tend to come in waves tied to local resistance patterns and hospital tender cycles rather than steady month-to-month demand, so we keep flexible MOQs and don't force distributors to warehouse more than their actual pipeline calls for. Communication stays direct between our team and the buyer, without layers of intermediaries slowing down quotes or documentation requests. For wholesalers and hospital suppliers building out a critical care antibiotic portfolio, Colistimethate Sodium 1 MIU fills a specific and important gap, and getting it from a partner who understands both the pharmacology and the paperwork saves headaches that a lower price alone never will.
Colistimethate Sodium for Injection 2 MIU
Ask any ICU pharmacist which antibiotics they hope they never have to reach for, and colistin usually makes the list, not because it doesn't work but because reaching for it means the infection has already outsmarted the safer first-line options. Colistimethate Sodium in the 2 MIU strength is the middle ground most institutional pharmacies keep in stock, sized to cover a typical adult dose without requiring a nurse to reconstitute and combine multiple smaller vials at 3am. The drug itself is a polymyxin antibiotic, active against the gram-negative organisms that cause the most stubborn hospital-acquired infections: ventilator-associated pneumonia, bloodstream infections in ICU patients, and complicated UTIs where Pseudomonas or carbapenem-resistant Enterobacteriaceae have already defeated the usual regimen. It's not a first date kind of drug. It's the one you call when everything else has been tried. Because colistin's therapeutic window sits close to its toxic threshold, the strength stocked matters as much as the drug itself. A 2 MIU vial lets clinical staff dose more precisely without wasting product or splitting vials mid-shift, which sounds like a small operational detail until you're the pharmacy tech doing it for the fourth time in a night. We supply this strength specifically because importers have told us, repeatedly, that it's the one their hospital customers actually reorder most. Manufacturing colistin at consistent potency requires tight process control, and we source exclusively from partners holding WHO-GMP certification with documented cold-chain handling from lyophilization onward. Every shipment carries a full certificate of analysis, stability data package, and the regulatory documentation that customs and hospital procurement teams require before a critical care antibiotic clears their system, because incomplete paperwork on a last-resort antibiotic gets flagged faster than on almost any other product category. Demand for this molecule tends to spike unpredictably, tied to local resistance surveillance data rather than a steady calendar, so we keep order quantities flexible rather than forcing distributors into bulk commitments that don't match their actual tender cycles. Fifteen years in the export business has made one thing clear: the relationships that last are the ones where a distributor can call, ask a direct question about batch documentation or lead time, and get a straight answer from someone who actually knows the shipment. For wholesalers and hospital suppliers who need a dependable source of last-line gram-negative coverage, Colistimethate Sodium 2 MIU rounds out a critical care antibiotic portfolio in the strength that clinical teams reach for most often.
Clarithromycin for Injection 500mg
A patient who can't swallow a tablet still needs their pneumonia treated, and that's the entire reason Clarithromycin exists in injectable form. Oral clarithromycin has been a workhorse macrolide antibiotic for decades, but hospitalised patients on ventilators, those in post-surgical recovery, or anyone with a compromised gut can't rely on a pill making it past the stomach lining, which is where the IV formulation earns its place on the hospital formulary. Each 500mg vial contains clarithromycin lactobionate, reconstituted first with sterile water and then diluted further before administration as a slow IV infusion, never as a bolus injection and never intramuscularly. It's indicated for community-acquired pneumonia, bacterial bronchitis, and skin or soft tissue infections where oral therapy isn't practical, and it retains the broad gram-positive and gram-negative coverage that makes macrolides useful across a wide range of respiratory infections. The reconstitution chemistry on this molecule is genuinely finicky. It requires the correct diluent in the correct sequence, or the solution precipitates, and a batch that doesn't dissolve cleanly is a batch a hospital pharmacist sends straight back. We work with manufacturers who've refined their lyophilization and fill process specifically to avoid this problem, which sounds like a minor technical point until you're the distributor explaining to a hospital why half a shipment came back. For importers stocking hospital antibiotic ranges, having a supplier who can move quickly on documentation matters just as much as the product itself. Every batch we export ships with certificate of analysis, GMP compliance certification, and stability data covering the full claimed shelf life, so customs clearance and hospital pharmacy intake don't stall waiting on missing paperwork. Flexible order quantities mean a smaller regional distributor can stock a reasonable volume without committing to a container load they can't move before expiry. What distinguishes Clarithromycin for Injection from some of the flashier newer antibiotics is that demand for it is steady rather than spiky, tied to routine respiratory infection season rather than resistance outbreaks, which makes it a dependable, predictable line item for a distributor building a recurring order pattern. After 15 years exporting hospital-grade injectables from India, that predictability is exactly the kind of product relationship that keeps a partnership going year after year, backed by clear communication and delivery timelines a buyer can actually plan around. For hospital suppliers and pharmaceutical wholesalers rounding out a respiratory antibiotic portfolio, this 500mg vial fills the gap between oral therapy and the heavier IV antibiotics reserved for resistant infections.